The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...
Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...
Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...
The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...
The LP.8.1 sublineage selection is based on guidance from the FDA, which stated that LP.8.1 is the preferred sublineage of a monovalent JN.1-lineage-based COVID-19 vaccine for use in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results